<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080743</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000355145</org_study_id>
    <secondary_id>DMS-0236</secondary_id>
    <secondary_id>ZENECA-IRUSIRES0162</secondary_id>
    <nct_id>NCT00080743</nct_id>
  </id_info>
  <brief_title>Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer</brief_title>
  <official_title>ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norris Cotton Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Hormone therapy using tamoxifen may fight breast cancer by blocking the use of&#xD;
      estrogen by the tumor cells. Combining gefitinib with tamoxifen may be effective in killing&#xD;
      tumor cells that have become resistant (stopped responding) to tamoxifen.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving gefitinib together with&#xD;
      tamoxifen works compared to gefitinib alone in treating patients with metastatic breast&#xD;
      cancer that has stopped responding to tamoxifen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the rate of clinical benefit in patients with tamoxifen-resistant breast cancer&#xD;
           treated with gefitinib with or without tamoxifen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Determine whether changes in fludeoxyglucose F 18 uptake by positron emission tomography&#xD;
           scan and changes in plasma DNA levels are indicators of an early response to gefitinib&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified according to population (intent-to-treat population comprising all patients who&#xD;
      receive 1 dose of treatment vs a subset of the intent-to-treat population, excluding patients&#xD;
      with nonmeasurable/evaluable only disease). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral tamoxifen once daily. Beginning 14 days after the start of&#xD;
           tamoxifen, patients receive oral gefitinib once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily. Beginning 14 days after the start of&#xD;
           placebo, patients receive oral gefitinib as in arm I.&#xD;
&#xD;
      In both arms, treatment continues for 26 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 46 patients (23 per treatment arm) will be accrued for this&#xD;
      study within 23 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate (complete response, partial response, and stable disease) for 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen 20 mg po once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator one tablet po once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>250 mg po once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>ZD1839, Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>20 mg po once daily</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One pill po once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Initial clinical benefit from tamoxifen for metastatic disease, defined by 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Stable disease for 24 weeks or longer&#xD;
&#xD;
               -  Objective tumor response&#xD;
&#xD;
          -  Documentation of clinical progression on tamoxifen within the past 6 weeks&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen or progesterone receptor positive on most recently analyzed biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with asymptomatic chronic stable radiographic changes are eligible&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to gefitinib&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell carcinoma or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent trastuzumab (Herceptin®)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since other prior tamoxifen&#xD;
&#xD;
          -  No concurrent hormone replacement therapy&#xD;
&#xD;
          -  No other concurrent antiestrogens, including raloxifene&#xD;
&#xD;
          -  No concurrent aromatase inhibitors&#xD;
&#xD;
          -  No concurrent megestrol&#xD;
&#xD;
          -  Concurrent systemic steroids for reasons other than skin toxicity allowed provided the&#xD;
             steroids were initiated before study entry AND dose remains stable&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Concurrent palliative radiotherapy as short-term treatment for symptomatic bone&#xD;
             metastases allowed provided other evaluable sites of disease are present AND treatment&#xD;
             lasts no more than 14 days&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery&#xD;
&#xD;
          -  No concurrent surgery during and for 7 days after study treatment&#xD;
&#xD;
          -  No concurrent ophthalmic surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy (except alopecia)&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Systemic retinoids&#xD;
&#xD;
               -  CYP3A4 inhibitors (e.g., itraconazole)&#xD;
&#xD;
               -  Drugs that cause significant sustained elevation in gastric pH ≥ 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary N. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>August 4, 2009</last_update_submitted>
  <last_update_submitted_qc>August 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gary N. Schwartz</name_title>
    <organization>Dartmouth-Hitchcock Medical Center</organization>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

